Who Exports Etoposide from India — 237 Suppliers Behind a $10.8M Market
India's etoposide export market is supplied by 237 active exporters who collectively shipped $10.8M across 2,129 shipments. INTAS PHARMACEUTICALS LIMITED leads with a 44.5% market share, followed by FRESENIUS KABI ONCOLOGY LIMITED and VENUS REMEDIES LIMITED. The top 5 suppliers together control 80.3% of total export value, reflecting a concentrated market structure.
Top Etoposide Exporters from India — Ranked by Export Value
INTAS PHARMACEUTICALS LIMITED is the leading etoposide exporter from India, holding a 44.5% share of the $10.8M market across 2,129 shipments from 237 exporters. The top 5 suppliers — INTAS PHARMACEUTICALS LIMITED, FRESENIUS KABI ONCOLOGY LIMITED, VENUS REMEDIES LIMITED, MYLAN LABORATORIES LIMITED, HETERO LABS LIMITED — collectively control 80.3% of total export value, indicating a highly concentrated market. Individual shares are: INTAS PHARMACEUTICALS LIMITED (44.5%), FRESENIUS KABI ONCOLOGY LIMITED (17.3%), VENUS REMEDIES LIMITED (9.1%), MYLAN LABORATORIES LIMITED (5.1%), HETERO LABS LIMITED (4.3%).
Top Etoposide Exporters from India
Ranked by export value · 237 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | INTAS PHARMACEUTICALS LIMITED PHR DRUGS&MEDI ETOPOSIDE INJ.USP 20MG/MLPHARMA DRUGS & MEDI ETOPOSIDE INJ,20MG/METOPOSIDE VIATRIS 200MG/10ML 10S FRANCE TAX VAL 11526820.13 | $4.8M | 11 | 44.5% |
| 2 | FRESENIUS KABI ONCOLOGY LIMITED ETOPOSIDE INJ. 100MG/5ML VIALPHARMA DRUGS AND MEDI CAVEP ETOPOSIDE 10ETOPOSIDE-KABI INJ. 100MG/5ML VIAL | $1.9M | 20 | 17.3% |
| 3 | VENUS REMEDIES LIMITED ETOPOSIDE INJECTION USP 100MG 5ML 65224VIALSPHARMA DRUGS AND MEDI CAVEP ETOPOSIDE 10FYTOSID INJ. USP 100MG/5ML V | $988.8K | 20 | 9.1% |
| 4 | MYLAN LABORATORIES LIMITED ETOPOSIDE VIATRIS 200MG/10ML 10S FRANCE TAX VAL 11526820.13ETOPOSIDE VIATRIS 200MG/10ML 10S FRANCE TAX VAL 11169494.87ETOPOSIDE VIATRIS 200MG/10ML 10S FRANCE TAX VAL 10828569.62 | $547.6K | 2 | 5.1% |
| 5 | HETERO LABS LIMITED ETOPOSIDE ACTE 1X1S ETOPOSIDE INJBATPOSID 50 MG CAPSULESBIOSIDE 100MG/5ML INJ. | $467.0K | 2 | 4.3% |
| 6 | MEDORBIS TRADE LLP ETOPOSIDE INJECTION USP 100MG 5ML 65224VIALSETOPOSIDE INJECTION USP EACETOPOSIDE INJECTION USP 100MG/5ML(6400 V | $338.1K | 2 | 3.1% |
| 7 | INTAS PHARMACEUTICALS LTD PHR DRUGS&MEDI ETOPOSIDE INJ.USP 20MG/MLPHARMA DRUGS & MEDI ETOPOSIDE INJ,20MG/METOPOSIDE VIATRIS 200MG/10ML 10S FRANCE TAX VAL 11526820.13 | $294.6K | 6 | 2.7% |
| 8 | GETWELL PHARMACEUTICALS | $136.2K | 9 | 1.3% |
| 9 | NV REMEDIES PRIVATE LIMITED PHARMA DRUGS & MEDI ETOPOSIDE INJ,20MG/MPHARMA DRUGS & MEDI ETOPOSIDE INJ USP,20PHARMA DRUG&MED:ETOPOSIDE INJ,20MG/ML,10 | $132.6K | 3 | 1.2% |
| 10 | KHANDELWAL LABORATORIES PRIVATE LIMITED | $98.1K | 5 | 0.9% |
| 11 | BETA DRUGS LIMITED | $96.4K | 8 | 0.9% |
| 12 | GETWELL PHARMA INDIA PRIVATE LIMITED | $96.1K | 6 | 0.9% |
| 13 | UNITED BIOTECH PRIVATE LIMITED | $65.9K | 10 | 0.6% |
| 14 | RUS MED EXPORTS PVT. LTD. | $48.0K | 1 | 0.4% |
| 15 | AQUARIUS ENTERPRISES | $44.6K | 1 | 0.4% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Etoposide exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Intas Pharmaceuticals Limited | Warning Letter, November | Yes, as of April 200 | Yes | Multiple approvals | Received FDA Warning Letter in November 2023 for CGMP violations at Matoda facil |
| Mylan Laboratories Limited | Approved | Yes, as of April 202 | Yes | Multiple approvals | WHO-GMP certified in April 2025; maintains FDA approval status. (extranet.who.in |
| Venus Remedies Limited | Not Listed | Yes | Yes | Not Listed | WHO-GMP certified; no FDA listing found. |
| Hetero Labs Limited | Approved | Yes | Yes | Multiple approvals | WHO-GMP certified; holds multiple FDA approvals. |
| Fresenius Kabi Oncology Limited | Approved | Yes | Yes | Multiple approvals | WHO-GMP certified; maintains FDA approval status. |
| Medorbiz Trade LLP | Not Listed | No | No | Not Listed | No regulatory certifications found. |
| Getwell Pharmaceuticals | Not Listed | Yes | Yes | Not Listed | WHO-GMP certified; no FDA listing found. |
| NV Remedies Private Limited | Not Listed | No | No | Not Listed | No regulatory certifications found. |
| Khandelwal Laboratories Private Limited | Not Listed | Yes | Yes | Not Listed | WHO-GMP certified; no FDA listing found. |
| Beta Drugs Limited | Not Listed | Yes | Yes | Not Listed | WHO-GMP certified; no FDA listing found. |
TransData Nexus reviewed the regulatory standing of 10 leading Etoposide exporters from India. 3 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 8 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Etoposide sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a pivotal hub for active pharmaceutical ingredients (APIs) and bulk drug manufacturing. The city hosts over 800 pharmaceutical companies, including major players like Dr. Reddy’s Laboratories and Aurobindo Pharma. The presence of Genome Valley, India's first biotech cluster, underscores Hyderabad's significance in biotech and pharmaceutical research and development.
The city's advanced infrastructure and skilled workforce make it a strategic location for the production of APIs like Etoposide. Companies in Hyderabad benefit from proximity to research institutions and a supportive regulatory environment, facilitating efficient production and export processes.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations and finished dosage forms. Gujarat contributes nearly 28% of India's pharmaceutical production and is home to leading companies such as Zydus Lifesciences, Intas Pharmaceuticals, and Torrent Pharmaceuticals.
Intas Pharmaceuticals Limited, headquartered in Ahmedabad, is the top exporter of Etoposide, accounting for $4.8 million (44.5%) of total exports. The region's robust infrastructure, including ports and logistics networks, supports efficient manufacturing and distribution, making it a key player in Etoposide exportation.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt in Maharashtra serves as a critical export gateway for pharmaceutical products. Maharashtra leads the country with 40 pharmaceutical clusters, providing a dense network of manufacturing units.
Companies in this region benefit from well-established logistics and proximity to major ports, facilitating the export of pharmaceuticals like Etoposide to international markets. The region's infrastructure and regulatory support make it a strategic location for companies aiming to expand their global footprint.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh is recognized as a significant pharmaceutical manufacturing hub, particularly for generic drugs and antibiotics. The region offers tax incentives and a favorable regulatory environment, attracting numerous pharmaceutical companies.
While not a primary center for Etoposide production, the cost advantages and supportive policies in Baddi-Nalagarh make it a potential area for future investment in API manufacturing.
5Sourcing Recommendations
- Diversify Supplier Base: While Intas Pharmaceuticals Limited is the leading exporter of Etoposide, accounting for 44.5% of exports, consider engaging with other significant suppliers such as Fresenius Kabi Oncology Limited (17.3%) and Venus Remedies Limited (9.1%) to mitigate supply chain risks.
- Leverage Regional Strengths: Utilize the specialized capabilities of different clusters—Hyderabad for API production, Ahmedabad-Vadodara for formulations, and Mumbai-Thane-Raigad for export logistics—to optimize the supply chain.
- Monitor Regulatory Developments: Stay informed about government initiatives like the Strengthening of Pharmaceutical Industry (SPI) scheme, which allocates funds to enhance infrastructure in pharma clusters, potentially impacting production capacities and costs.
- Assess Infrastructure and Logistics: Evaluate the logistical advantages of clusters like Mumbai-Thane-Raigad, which offer proximity to major ports, facilitating efficient export processes for Etoposide.
By strategically sourcing from these clusters and considering the unique advantages each offers, TransData Nexus can enhance its supply chain resilience and efficiency in procuring Etoposide.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Etoposide exporters from India
Intas Pharmaceuticals Limited — Intas acquires Prothya Biosolutions to expand plasma-derived medicines
Intas Pharmaceuticals, through its subsidiary Accord Plasma, completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries. This acquisition adds Prothya’s European plasma fractionation facilities and collection network, including operations in Amsterdam, Brussels, and Hungary, to Intas's global manufacturing footprint, enhancing production and access to plasma-derived medicinal products. - IMPACT: The acquisition is expected to bolster Intas's capabilities in producing plasma-derived medicines, potentially influencing its Etoposide export operations.
Impact: The acquisition is expected to bolster Intas's capabilities in producing plasma-derived medicines, potentially influencing its Etoposide export operations.
Common Questions — Etoposide Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which etoposide supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, INTAS PHARMACEUTICALS LIMITED leads with 580 recorded shipments worth $4.8M. FRESENIUS KABI ONCOLOGY LIMITED (126 shipments) and VENUS REMEDIES LIMITED (139 shipments) are also established high-volume exporters.
Q How many etoposide manufacturers are there in India?
India has 237 active etoposide exporters with a combined export market of $10.8M across 2,129 shipments to 122 countries. The top 5 suppliers hold 80.3% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for etoposide from India?
Average FOB unit price: $4.05 per unit, ranging from $0.01 to $940.17. Average shipment value: $5.1K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 237 verified Indian exporters of Etoposide ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 2,129 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 122 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2,129 Verified Shipments
237 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists